More Studies on Metformin and Survival

In this update, we review two recent papers that address the question of people with type 2 diabetes who take metformin living longer than people without the disease who don’t, but without the flaw in the 2014 study. We find that, as expected, metformin is a good diabetes drug but shows no sign of being a longevity therapeutic.

Read more...

Set My Heart Free: Two AmyloSENS Therapies Targeting Cardiac Amyloid in Clinical Trials

TTR cardiac amyloid contributes to heart failure and appears to limit the lives of the longest-lived humans. One AmyloSENS antibody shows high promise to remove this amyloid and restore function in the aging heart in an early-stage clinical trial. A second such antibody is coming close behind it, and a tiny number of people’s immune systems appear to generate such antibodies on their own.

Read more...

From Parachutes to Jetpacks: Clearing Brain Beta-Amyloid with Donanemab or Lecanemab Works, Though More Must be Done

Another clinical trial has now proven that a second AmyloSENS rejuvenation biotechnology that clears beta-amyloid aggregates from the brain also slows down the slide into dementia in people in the early stages of Alzheimer’s disease, but this development is only the beginning.

Read more...

SENSible Question: Billionaires Redux

A supporter raises a new angle on an old concern: might fabulously wealthy people hoard longevity therapeutics for themselves? The context for the question and the motivation behind it are different, but the answer is still “no.” Rejuvenation biotechnology will be widely available to aging people, and SENS Research Foundation will work at the front end and the back end to ensure that access to longevity therapeutics expands as quickly and as widely as possible.

Read more...

An Oil Change is Not a Gasket Change: Insights from the Interaction of “Old Blood” and Senolytic Therapy

When blood from a biologically aged animal is transfused into a young one, the young animal suffers “pro-aging” effects. By contrast, reducing the burden of “pro-aging” signaling factors in old blood is not enough to remove existing damage from a similar-aged mouse’s biologically aged tissues.

Read more...

Kneecapped by Aging: New and Scrutinized Science Suggests Why the UNITY Osteoarthritis Trial Failed

UNITY Biotechnology was the first senolytic startup out of the gate, and the failure of its Phase II trial in osteoarthritis was a crushing disappointment. A careful look back at the underlying science and three new scientific papers give us a good idea why and suggest ways to move forward.

Read more...

SENSible Question: How Might Cyclarity’s UDP-003 Compare to EDTA Chelation?

A supporter asks us to compare the expected benefits of Cyclarity’s UDP-003 to chelation therapy. Although both target the age-related scourge of atherosclerotic cardiovascular disease (ASCVD), EDTA (if it works) dampens down the worst aspects of having ASCVD, while UPD-003 is a SENS “damage-repair” therapeutic which is expected to remove the underlying damage itself and reverse the disease process.

Read more...

A TAME Attempt to Slow Aging Part 5: Winning the Game with a Weak Hand

Metformin has been proposed as an “anti-aging drug,” and scientists are organizing TAME, a major clinical trial to test the idea. In the final installment of this 5-part series, we look at TAME itself: how it’s structured, how it’s justified, and how the results could impact the push for longevity therapeutics.

Read more...

Use of this Web site constitutes acceptance of the Terms of Use and Privacy Policy.

© 2023 SENS Research Foundation – ALL RIGHTS RESERVED

Thank you for Subscribing to the SENS Research Foundation Newsletter.

You can also

or

You can